Skip to content

A New Landscape: Biosimilars in Autoimmune Indications

Checklists for workflow considerations relating to adalimumab biosimilars

Nonmedical Switching From Originators to Biosimilars: Does the Nocebo Effect Explain Treatment Failures and Adverse Events in Rheumatology and Gastroenterology?

Era of biosimilars in rheumatology: reshaping the healthcare environment

The Future of Biosimilars: Maximizing Benefits Across Immune-Mediated Inflammatory Diseases

Rheumatology Biosimilars Landscape

Adalimumab was approved by Food and Drug Administration (FDA) in 2002 for the treatment of rheumatoid arthritis and, in subsequent years, gained approval for the treatment of additional conditions, including plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, hidradenitis suppurativa, inflammatory bowel disease, and uveitis. In 2023, several adalimumab biosimilars from different manufacturers are anticipated to enterContinue reading “Rheumatology Biosimilars Landscape”

Humira™ biosimilar landscape overview

An Update Review of Biosimilars of Adalimumab in Psoriasis – Bioequivalence and Interchangeability

Switching between reference adalimumab and biosimilars in chronic immune-mediated inflammatory diseases: A systematic literature review

A Review of the Totality of Evidence Supporting the Development of the First Adalimumab Biosimilar ABP 501